Molecular methods for the detection of mutations
We report the results of a collaborative study aimed at developing reliable, direct assays for mutation in human cells. The project used common lymphoblastoid cell lines, both with and without mutagen treatment, as a shared resource to validate the development of new molecular methods for the detect...
Saved in:
Published in: | Teratogenesis, carcinogenesis, and mutagenesis Vol. 20; no. 6; pp. 357 - 386 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
John Wiley & Sons, Inc
2000
Wiley-Liss |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | We report the results of a collaborative study aimed at developing reliable, direct assays for mutation in human cells. The project used common lymphoblastoid cell lines, both with and without mutagen treatment, as a shared resource to validate the development of new molecular methods for the detection of low‐level mutations in the presence of a large excess of normal alleles. As the “gold standard,” hprt mutation frequencies were also measured on the same samples. The methods under development included i) the restriction site mutation (RSM) assay, in which mutations lead to the destruction of a restriction site; ii) minisatellite length‐change mutation, in which mutations lead to alleles containing new numbers of tandem repeat units; iii) loss of heterozygosity for HLA epitopes, in which antibodies can be used to direct selection for mutant cells; iv) multiple fluorescence‐based long linker arm nucleotides assay (mf‐LLA) technology, for the detection of substitutional mutations; v) detection of alterations in the TP53 locus using a (CA) array as the target for the screening; and vi) PCR analysis of lymphocytes for the presence of the BCL2 t(14:18) translocation. The relative merits of these molecular methods are discussed, and a comparison made with more “traditional” methods. Teratogenesis Carcinog. Mutagen. 20:357–386, 2000. © 2000 Wiley‐Liss, Inc. |
---|---|
Bibliography: | ark:/67375/WNG-XKDPQ9Z8-W EU Environment - No. EV5V CT920197 ArticleID:TCM5 Wellcome Trust (JALA) - No. 038225/Z/93/Z istex:06DCE1570F702E6785873350094FA520F3CA9618 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 0270-3211 1520-6866 |
DOI: | 10.1002/1520-6866(2000)20:6<357::AID-TCM5>3.0.CO;2-G |